Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 306

1.

Detection of circulating tumor cells in different stages of prostate cancer.

Thalgott M, Rack B, Maurer T, Souvatzoglou M, Eiber M, Kreß V, Heck MM, Andergassen U, Nawroth R, Gschwend JE, Retz M.

J Cancer Res Clin Oncol. 2013 May;139(5):755-63. doi: 10.1007/s00432-013-1377-5. Epub 2013 Jan 29.

PMID:
23358719
2.

Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.

Goodman OB Jr, Symanowski JT, Loudyi A, Fink LM, Ward DC, Vogelzang NJ.

Clin Genitourin Cancer. 2011 Sep;9(1):31-8. doi: 10.1016/j.clgc.2011.04.001. Epub 2011 Jun 25.

PMID:
21705286
3.

Prognostic significance of circulating tumor cell count in patients with metastatic hormone-sensitive prostate cancer.

Resel Folkersma L, San José Manso L, Galante Romo I, Moreno Sierra J, Olivier Gómez C.

Urology. 2012 Dec;80(6):1328-32. doi: 10.1016/j.urology.2012.09.001. Epub 2012 Oct 10.

PMID:
23063057
4.

Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.

Bitting RL, Healy P, Halabi S, George DJ, Goodin M, Armstrong AJ.

Urol Oncol. 2015 Mar;33(3):110.e1-9. doi: 10.1016/j.urolonc.2014.09.002. Epub 2015 Jan 13.

PMID:
25595577
5.
6.

Immunomagnetic quantification of circulating tumoral cells in patients with prostate cancer: clinical and pathological correlation.

Resel Folkersma L, Olivier Gómez C, San José Manso L, Veganzones de Castro S, Galante Romo I, Vidaurreta Lázaro M, de la Orden GV, Arroyo Fernández M, Díaz Rubio E, Silmi Moyano A, Maestro de Las Casas MA.

Arch Esp Urol. 2010 Jan-Feb;63(1):23-31.

PMID:
20157216
7.

Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.

Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP 3rd, Datar RH, Garzotto M, Mack PC, Lara P Jr, Higano CS, Hussain M, Thompson IM Jr, Cote RJ, Vogelzang NJ.

J Clin Oncol. 2014 Apr 10;32(11):1136-42. doi: 10.1200/JCO.2013.51.7417. Epub 2014 Mar 10.

8.

Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer.

Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M, Scher HI.

Clin Cancer Res. 2007 Dec 1;13(23):7053-8.

9.

Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors.

Goodman OB Jr, Fink LM, Symanowski JT, Wong B, Grobaski B, Pomerantz D, Ma Y, Ward DC, Vogelzang NJ.

Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1904-13. doi: 10.1158/1055-9965.EPI-08-1173.

10.

Circulating tumor cells versus objective response assessment predicting survival in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapy.

Thalgott M, Heck MM, Eiber M, Souvatzoglou M, Hatzichristodoulou G, Kehl V, Krause BJ, Rack B, Retz M, Gschwend JE, Andergassen U, Nawroth R.

J Cancer Res Clin Oncol. 2015 Aug;141(8):1457-64. doi: 10.1007/s00432-015-1936-z. Epub 2015 Feb 24.

PMID:
25708944
11.

Evaluation of circulating tumor cells in patients with breast cancer: multi-institutional clinical trial in Japan.

Yagata H, Nakamura S, Toi M, Bando H, Ohno S, Kataoka A.

Int J Clin Oncol. 2008 Jun;13(3):252-6. doi: 10.1007/s10147-007-0748-9. Epub 2008 Jun 14.

PMID:
18553236
12.

Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer.

Gonzales JC, Fink LM, Goodman OB Jr, Symanowski JT, Vogelzang NJ, Ward DC.

Clin Genitourin Cancer. 2011 Sep;9(1):39-45. doi: 10.1016/j.clgc.2011.05.008. Epub 2011 Jul 1.

PMID:
21723797
13.

The current role of circulating tumor cells in the diagnosis and management of bone metastases in advanced prostate cancer.

Saad F, Pantel K.

Future Oncol. 2012 Mar;8(3):321-31. doi: 10.2217/fon.12.3. Review.

PMID:
22409467
14.

Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer.

Lindsay CR, Le Moulec S, Billiot F, Loriot Y, Ngo-Camus M, Vielh P, Fizazi K, Massard C, Farace F.

BMC Cancer. 2016 Feb 29;16:168. doi: 10.1186/s12885-016-2192-6.

15.

Clinical significance of circulating tumor cells in blood from patients with gastrointestinal cancers.

Hiraiwa K, Takeuchi H, Hasegawa H, Saikawa Y, Suda K, Ando T, Kumagai K, Irino T, Yoshikawa T, Matsuda S, Kitajima M, Kitagawa Y.

Ann Surg Oncol. 2008 Nov;15(11):3092-100. doi: 10.1245/s10434-008-0122-9. Epub 2008 Sep 3.

PMID:
18766405
16.

[Detection of circulating tumor cells from peripheral blood in prostate cancer].

Thalgott M, Heck MM, Pantel K.

Urologe A. 2014 Apr;53(4):509-13. doi: 10.1007/s00120-014-3444-1. Review. German.

PMID:
24671249
17.

Circulating levels of transforming growth factor-βeta (TGF-β) and chemokine (C-X-C motif) ligand-1 (CXCL1) as predictors of distant seeding of circulating tumor cells in patients with metastatic breast cancer.

Divella R, Daniele A, Savino E, Palma F, Bellizzi A, Giotta F, Simone G, Lioce M, Quaranta M, Paradiso A, Mazzocca A.

Anticancer Res. 2013 Apr;33(4):1491-7.

PMID:
23564790
18.

Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?

Dawood S, Broglio K, Valero V, Reuben J, Handy B, Islam R, Jackson S, Hortobagyi GN, Fritsche H, Cristofanilli M.

Cancer. 2008 Nov 1;113(9):2422-30. doi: 10.1002/cncr.23852.

19.

Detection of Circulating Tumor Cells in Locally Advanced High-risk Prostate Cancer During Neoadjuvant Chemotherapy and Radical Prostatectomy.

Thalgott M, Rack B, Horn T, Heck MM, Eiber M, Kübler H, Retz M, Gschwend JE, Andergassen U, Nawroth R.

Anticancer Res. 2015 Oct;35(10):5679-85.

PMID:
26408743
20.

Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease.

Chen BT, Loberg RD, Neeley CK, O'Hara SM, Gross S, Doyle G, Dunn RL, Kalikin LM, Pienta KJ.

Urology. 2005 Mar;65(3):616-21.

PMID:
15780403

Supplemental Content

Support Center